ClinicalTrials.gg
Not yet recruitingNCT07767240ERAUpdated Aug 17, 2026

ERA in Young Primary Infertile RIF Patients

An observational study in Recurrent Implantation Failure, sponsored by ShangHai Ji Ai Genetics & IVF Institute. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by ShangHai Ji Ai Genetics & IVF Institute · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

This study aims to evaluate the clinical efficacy of transcriptome-based endometrial receptivity analysis (tb-ERA) and investigate the molecular mechanisms of abnormal receptivity in young women with unexplained recurrent implantation failure (RIF).

Read the detailed description

Young women with recurrent implantation failure (RIF) will be prospectively recruited and classified based on their Window of Implantation (WOI) status. Clinical outcomes will be compared between patients undergoing personalized embryo transfer (pET) and those receiving standard transfer. Concurrently, endometrial tissues collected at P+3 and P+5 will undergo RNA sequencing to elucidate the molecular mechanisms underlying abnormal receptivity. Integrating these clinical and transcriptomic data, we aim to develop a clinical prediction model for displaced WOI and validate the efficacy of pET in improving pregnancy outcomes for this specific population.

02

Conditions studied

  • Recurrent Implantation Failure

Keywords

  • endometrial receptivity analysis
  • recurrent implantation failure
03

In context

Lead sponsor

ShangHai Ji Ai Genetics & IVF Institute is the lead sponsor of 26 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will enroll women aged ≤ 35 years with a BMI of 18-25 kg/m². The RIF cohort includes patients with primary infertility and ≥ 3 failed transfers of high-quality embryos, further divided into the RIF-ERA group and the RIF non-ERA group (active comparator). The control group consists of patients undergoing their first IVF-ET cycle for tubal factor infertility, with no history of biochemical pregnancy or miscarriage. Patients with known causes of implantation failure will be excluded from all groups. All participants will provide written informed consent.

Eligibility criteria

  • RIF Cohort - Inclusion Criteria

    1. Age ≤ 35 years; 18-25 kg/m².
    2. ≥ 3 failed transfers of high-quality embryos.
    3. No history of spontaneous or FET-related pregnancy, including biochemical pregnancy (primary infertility).
    4. Written provided.
  • RIF Cohort - Exclusion Criteria

    1. Known factors associated with RIF, including: uterine anatomical abnormalities (malformations, adhesions, polyps, submucosal fibroids, adenomyosis) and hydrosalpinx
    2. Endocrine disorders (PCOS, thyroid dysfunction, hyperprolactinemia)
    3. Reproductive immunological abnormalities, thrombophilia and infectious factors, abnormal semen parameters,
    4. Chromosomal abnormalities in either partner (planned PGT-SR) or monogenic disease (planned PGT-M).
    5. Severe medical/surgical conditions contraindicating pregnancy.
    6. Any other condition deemed unsuitable by the investigators.
  • Control Group - Inclusion Criteria

    1. Age ≤ 35 years; BMI 18-25 kg/m².
    2. First IVF-ET cycle due to tubal factor infertility.
    3. No history of biochemical pregnancy or miscarriage.
    4. Written informed consent provided.
  • Control Group - Exclusion Criteria 1. Same as RIF Cohort Exclusion Criteria. Additionally, participants with an abnormal ERA result will be excluded from the control group.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • ERA cohort

    RIF patients with tb-ERA and personalized embryo transfer

    Other: tb-ERA and personalized embryo transfer

  • Active Comparator

    RIF patients receiving standard transfer

  • Control

    Non-RIF patients, receiving the first-time embryo transfer

Interventions

  • Othertb-ERA and personalized embryo transfer

    tb-ERA and personalized embryo transfer

06

What researchers measure

Primary outcomes

  1. Ongoing pregnancy

    Ongoing pregnancy is defined as viable pregnancy beyond 12 weeks' gestation.

    Time frame: 12 weeks after embryo transfer

Secondary outcomes

  1. Clinical pregnancy

    Pregnancy with ultrasound-confirmed intrauterine gestational sac(s)

    Time frame: 6 to 8 weeks after embryo transfer

  2. Implantation rate

    The proportion of gestational sacs observed divided by the total number of embryos transferred

    Time frame: 6 to 8 weeks after embryo transfer

Other outcomes

  1. Endometrial Receptivity Signature

    The proportion of young RIF patients diagnosed with a displaced Window of Implantation (either pre-receptive or post-receptive) based on Endometrial Receptivity Analysis (ERA)

    Time frame: Through ERA completion, an average of 1 month after sampling

07

Study locations

1 site
  • Shanghai Ji Ai Genetics and IVF Institute, Obstetrics and Gynecology Hospital, Fudan University
    Shanghai, Shanghai Municipality 200011, China
08

References and documents

Publications

  • Cao D, Liu Y, Cheng Y, Wang J, Zhang B, Zhai Y, Zhu K, Liu Y, Shang Y, Xiao X, Chang Y, Lee YL, Yeung WSB, Huang Y, Yao Y. Time-series single-cell transcriptomic profiling of luteal-phase endometrium uncovers dynamic characteristics and its dysregulation in recurrent implantation failures. Nat Commun. 2025 Jan 2;16(1):137. doi: 10.1038/s41467-024-55419-z. PubMed 39747825 ↗
  • Cimadomo D, Rienzi L, Conforti A, Forman E, Canosa S, Innocenti F, Poli M, Hynes J, Gemmell L, Vaiarelli A, Alviggi C, Ubaldi FM, Capalbo A. Opening the black box: why do euploid blastocysts fail to implant? A systematic review and meta-analysis. Hum Reprod Update. 2023 Sep 5;29(5):570-633. doi: 10.1093/humupd/dmad010. PubMed 37192834 ↗
  • Busnelli A, Reschini M, Cardellicchio L, Vegetti W, Somigliana E, Vercellini P. How common is real repeated implantation failure? An indirect estimate of the prevalence. Reprod Biomed Online. 2020 Jan;40(1):91-97. doi: 10.1016/j.rbmo.2019.10.014. Epub 2019 Oct 29. PubMed 31924493 ↗
  • Glujovsky D, Lattes K, Miguens M, Pesce R, Ciapponi A. Personalized embryo transfer guided by endometrial receptivity analysis: a systematic review with meta-analysis. Hum Reprod. 2023 Jul 5;38(7):1305-1317. doi: 10.1093/humrep/dead098. PubMed 37203432 ↗
  • Zhang WB, Li J, Li Q, Lu X, Chen JL, Li L, Chen H, Fu W, Chen JC, Lu BJ, Wu H, Sun XX. Endometrial transcriptome profiling of patients with recurrent implantation failure during hormone replacement therapy cycles. Front Endocrinol (Lausanne). 2024 Jan 30;14:1292723. doi: 10.3389/fendo.2023.1292723. eCollection 2023. PubMed 38352249 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data will be shared upon reasonable request to the corresponding author, subject to approval by the principal investigator and a signed data use agreement, following publication of the primary results. Data will be retained for a minimum of 5 years.

Supporting information: Study protocol

Time frame: Data will be retained for a minimum of 5 years.

Access criteria: De-identified individual patient data will be shared upon reasonable request to the corresponding author by email.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Aug 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2026
First posted
Aug 17, 2026
StartEst.
Aug 15, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07767240
Lead sponsor
ShangHai Ji Ai Genetics & IVF Institute
Responsible party
Sponsor
First posted
Aug 17, 2026
Start date
Aug 15, 2026 (estimated)
Primary completion
Aug 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 17, 2026

Study contacts

Yilun Sui, M.D.
Contact
965845006@qq.com
86-21-63459977
Lu Li, M.Sc.
Contact
86-21-63459977
Lu Li, M.Sc.
principal investigator · Shanghai Ji Ai Genetics and IVF Institute, Obstetrics and Gynecology Hospital, Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion